You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for MLi-2
MLi-2 is a potent and selective LRRK2 inhibitor (IC50 = 0.76-3.4 nM depending on assay), which exhibits >295-fold selectivity for over 300 kinases and a diverse panel of receptors and ion channels. MLi-2 is centrally bioavailable and active in vivo.
External Portal Information for MLi-2
Chemicalprobes.org and the Chemical Probes webpages of the Structural Genomics Consortium are portals that offer independent guidance on the selection and/or application of small molecules for research. The use of MLi-2 is reviewed on chemicalprobes.org and the SGC website.
Compound Libraries for MLi-2
Technical Data for MLi-2
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for MLi-2
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for MLi-2
The following data is based on the product molecular weight 379.46. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.27 mL||26.35 mL||52.71 mL|
|2.5 mM||1.05 mL||5.27 mL||10.54 mL|
|5 mM||0.53 mL||2.64 mL||5.27 mL|
|25 mM||0.11 mL||0.53 mL||1.05 mL|
References for MLi-2
References are publications that support the biological activity of the product.
Fell et al (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J.Pharmacol.Exp.Ther. 355 397 PMID: 26407721
If you know of a relevant reference for MLi-2, please let us know.
View Related Products by Product Action
Keywords: MLi-2, MLi-2 supplier, leucine-rich, repeat, kinase, 2, LRRK2, inhibitors, inhibits, potent, neuroprotective, neuronal, injury, parkinson's, parkinsons, 5756, Tocris Bioscience
1 Citation for MLi-2
Citations are publications that use Tocris products. Selected citations for MLi-2 include:
Henderson et al (2018) LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Acta Neuropathol Commun 6 45 PMID: 29855356
Do you know of a great paper that uses MLi-2 from Tocris? Please let us know.
Reviews for MLi-2
There are currently no reviews for this product. Be the first to review MLi-2 and earn rewards!
Have you used MLi-2?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.